Anemia

Normocytic Anemia

Use the reticulocyte response to distinguish blood loss, hemolysis and recovery from impaired erythropoiesis caused by kidney disease, inflammation, nutritional deficiency, endocrine disorders, medications or marrow disease.

Audience: internal medicine residents Last reviewed: July 2026

Bedside approach

Answer these questions first

Is the anemia acute? Compare with prior hemoglobin values and assess bleeding, fluid administration, phlebotomy, procedures and transfusions.
Is the marrow responding? Use the absolute reticulocyte count, corrected reticulocyte percentage or reticulocyte production index.
Is there hemolysis? Review LDH, bilirubin, haptoglobin, urinalysis, DAT and the peripheral smear.
Could this still be nutritional? Early iron, B12 or folate deficiency and mixed deficiencies may remain normocytic.
Is kidney disease sufficient to explain it? CKD commonly contributes but does not exclude iron deficiency, inflammation, bleeding, hemolysis or marrow disease.
Are other cell lines abnormal? Leukopenia, thrombocytopenia, blasts or dysplasia increase concern for marrow failure, infiltration or hematologic malignancy.

Urgent escalation

  • Hemodynamic instability or active major bleeding
  • Ischemic symptoms, syncope or severe hypoxemia
  • Rapid unexplained hemoglobin decline
  • Hemolysis with thrombocytopenia or organ injury
  • Circulating blasts or suspected acute leukemia
  • Severe reticulocytopenia in an immunocompromised patient
  • Pancytopenia with fever, bleeding or marrow-failure features

1. Initial evaluation

  1. Confirm the hemoglobin and review previous CBC values, transfusions, fluids and bleeding events.
  2. Obtain an absolute reticulocyte count and inspect the peripheral smear.
  3. Separate a regenerative pattern from impaired production.
  4. Check iron studies, kidney function, liver studies and hemolysis markers based on the clinical context.
  5. Consider B12, folate, thyroid testing, inflammatory disease, infection and medications.
  6. Escalate to marrow evaluation when anemia remains unexplained or additional cytopenias, dysplasia or blasts are present.

Common initial tests

Core tests

  • CBC with differential and prior-count review
  • Absolute reticulocyte count
  • Peripheral smear
  • Creatinine and estimated GFR
  • Ferritin, serum iron, TIBC and TSAT
  • LDH, bilirubin and haptoglobin
  • Urinalysis

Cause-directed tests

  • DAT
  • Vitamin B12 and folate
  • TSH
  • CRP or ESR when useful
  • SPEP, immunofixation and free light chains
  • Parvovirus testing
  • Bone-marrow aspirate and biopsy

2. Interpret the reticulocyte response

Pattern Likely mechanism Important causes
Appropriately increased response Marrow is responding to RBC loss or destruction Bleeding, hemolysis, recovery after treatment or marrow suppression, and recent erythropoietic stimulation
Inadequate response Reduced or ineffective erythropoiesis CKD, inflammation, iron/B12/folate deficiency, marrow disease, endocrine disease, medication toxicity, infection or nutritional deficiency
Mixed response More than one mechanism is present Hemolysis plus nutrient deficiency, bleeding plus CKD, inflammatory disease plus iron deficiency, or recent transfusion
A raw reticulocyte percentage may look elevated simply because the circulating RBC denominator is reduced. Use the absolute count or correct the percentage for anemia severity.

Interactive tools

Reticulocyte-response calculators

Corrected reticulocyte percentage

Enter the reticulocyte percentage and hematocrit.

Corrected retic = retic % × patient hematocrit ÷ reference hematocrit.

Reticulocyte production index

Enter the reticulocyte percentage and hematocrit.

RPI = corrected reticulocyte percentage ÷ maturation factor.

3. Increased reticulocyte response

Blood loss

  • Overt gastrointestinal, genitourinary or gynecologic bleeding
  • Occult gastrointestinal blood loss
  • Recent surgery, trauma or procedure
  • Retroperitoneal or soft-tissue bleeding
  • Frequent phlebotomy
Acute blood loss may initially remain normocytic with a hemoglobin that does not fully reflect the eventual deficit until fluid shifts occur.

Hemolysis

  • Autoimmune hemolytic anemia
  • Microangiopathic hemolysis
  • Mechanical valve or circulatory-device hemolysis
  • Enzyme or membrane disorders
  • Hemoglobinopathy
  • Infection or oxidant injury

Use the dedicated hemolysis guide when the laboratory and smear pattern suggest RBC destruction.

4. Inadequate reticulocyte response

Cause Supporting clues Next steps
CKD Reduced eGFR, chronicity and low or inappropriately normal reticulocyte response Exclude iron deficiency, inflammation, bleeding, hemolysis and nutritional deficiency before attributing all anemia to CKD.
Anemia of inflammation Chronic infection, autoimmune disease, cancer or inflammatory illness with reduced serum iron and reticulocyte response Interpret ferritin and TSAT together and look for coexisting absolute iron deficiency.
Early nutritional deficiency Normal MCV with low ferritin, borderline B12 or mixed deficiency Do not exclude iron, B12 or folate deficiency because the MCV is normal.
Endocrine disease Hypothyroidism, hypogonadism, adrenal disease or pituitary disease Use targeted endocrine testing based on symptoms and clinical context.
Marrow disease Additional cytopenias, dysplasia, blasts, monoclonal protein, constitutional symptoms or organomegaly Hematology evaluation and marrow testing when appropriate.
Pure red-cell aplasia Severe anemia with marked reticulocytopenia and relatively preserved platelets and neutrophils Review medications, thymoma, autoimmune disease, lymphoproliferative disorders and parvovirus B19.

5. Anemia and chronic kidney disease

CKD-associated anemia is usually hypoproliferative and commonly normocytic, but iron deficiency and inflammation frequently coexist. Correctable causes should be addressed before starting an erythropoiesis-stimulating agent or HIF-prolyl-hydroxylase inhibitor. [2]

Evaluate before attributing anemia to CKD

  • Iron status
  • Blood loss
  • Hemolysis
  • B12 and folate deficiency
  • Inflammation or infection
  • Medication effect
  • Marrow disease
ESA decisions depend on CKD stage, dialysis status, symptoms, transfusion risk, cardiovascular and thrombotic risk, iron status and shared decision-making. Use current nephrology and KDIGO guidance rather than a single universal hemoglobin target.

6. Anemia of inflammation

Anemia of inflammation is typically mild to moderate, normocytic and hypoproliferative. Serum iron and TSAT are commonly reduced, while ferritin may remain normal or elevated because it is an acute-phase reactant. [3]

Feature Absolute iron deficiency Anemia of inflammation
Ferritin Usually reduced Often normal or increased, but concurrent iron deficiency may lower it
Serum iron Reduced Reduced
TIBC or transferrin Often increased Often reduced or normal
TSAT Reduced Reduced
Reticulocyte response Inadequate until iron is restored Usually reduced
Absolute iron deficiency and inflammation frequently coexist. A “normal” ferritin does not automatically exclude iron deficiency in an inflamed patient.

7. When to consider bone-marrow evaluation

  • Persistent unexplained anemia
  • Progressive anemia despite correction of reversible causes
  • Leukopenia or thrombocytopenia
  • Peripheral-blood dysplasia
  • Circulating blasts
  • Marked reticulocytopenia
  • Concern for MDS, leukemia, aplastic anemia or infiltration
  • Monoclonal protein with concerning clinical features
A normal MCV does not exclude marrow disease. The smear, reticulocyte response, other cell lines and clinical trajectory are more useful than cell size alone.

8. Red-cell transfusion

For many hemodynamically stable hospitalized adults, restrictive transfusion strategies are recommended. Decisions should still incorporate symptoms, active bleeding, ischemia, cardiovascular disease, rate of decline and the broader clinical context. [4]

Do not transfuse solely because the anemia is normocytic or because a single threshold has been crossed. Treat the patient and the cause, not the MCV.

9. Resident summary

  1. Confirm the anemia and review the trend.
  2. Use the reticulocyte response to define the mechanism.
  3. High reticulocytes suggest bleeding, hemolysis or recovery.
  4. Low reticulocytes suggest impaired production.
  5. Normal MCV does not exclude iron, B12 or folate deficiency.
  6. CKD and inflammation commonly coexist with iron deficiency.
  7. Additional cytopenias, blasts or dysplasia increase concern for marrow disease.
  8. Transfusion decisions depend on symptoms and clinical context, not red-cell size.

10. Knowledge check

Question 1

A patient has normocytic anemia and a markedly increased corrected reticulocyte response. Which mechanism is most likely?

Question 2

A patient has normal MCV, low ferritin and low TSAT. Which interpretation is most accurate?

Question 3

A patient with CKD has worsening anemia. What should occur before assuming CKD is the sole cause?

Question 4

Severe isolated anemia with profound reticulocytopenia and preserved platelets and neutrophils should raise concern for:

References

  1. Oyedeji CI, Artz AS, Cohen HJ. How I treat anemia in older adults. Blood. 2024. Open article
  2. Kidney Disease: Improving Global Outcomes. Clinical Practice Guideline for Anemia in Chronic Kidney Disease. 2026. KDIGO guideline
  3. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019. Open article
  4. Carson JL, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023. AABB summary
  5. American Society of Hematology. Reflections on the reticulocyte count: the importance of a complete blood count. ASH review

Educational disclaimer

This guide is intended for clinician education and does not replace local laboratory reference ranges, institutional protocols, nephrology or hematology consultation, transfusion-service guidance or individualized clinical judgment. Active bleeding, severe symptomatic anemia, suspected TMA and marrow-failure syndromes require urgent local escalation.